DiabetologyNews.net

Diabetology Xagena

Xagena Mappa
Medical Meeting
Onco News
Mediexplorer.it

Prior studies found patients treated with sodium-glucose co-transporter-2 inhibitors ( SGLT-2i ) had lower rates of death and heart failure. Whether the benefits of SGLT-2 inhibitors vary based upon ...


A new Expert Consensus Decision Pathway issued by the American College of Cardiology ( ACC ) has recommended Empagliflozin ( Jardiance ) as the preferred SGLT2 inhibitor for its proven benefit in redu ...


The results from PIONEER 8, a phase 3a trial with oral Semaglutide ( Ozempic ) for the treatment of adults with type 2 diabetes. Oral Semaglutide is an investigational GLP-1 analogue taken once dail ...


New research presented at the annual meeting of the European Association for the Study of Diabetes ( EASD ) has shown how the glucose-lowering drug Lixisenatide ( Lyxumia ) can slow or prevent damage ...


Dulaglutide ( Trulicity ) significantly improves A1C ( average blood sugar concentration over two to three months ) when added to ongoing treatment with a sodium-glucose co-transporter-2 ( SGLT-2 ) in ...


Both type 1 ( T1DM ) and type 2 diabetes mellitus ( T2DM ) have been associated with bone fragility and increased fracture risk. However, little is known regarding the effect of anti-osteoporotic tr ...


Reduction in cardiovascular death and hospitalization for heart failure ( HHF ) was reported with the sodium-glucose cotransporter-2 inhibitor ( SGLT-2i ) Empagliflozin ( Jardiance ) in patients with ...


The pivotal inTandem1 phase 3 clinical trial of Sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C at 24 weeks in patients with type 1 diabetes on a backgroun ...


Findings from two phase 3a clinical trials for Semaglutide, an investigational glucagon-like peptide-1 ( GLP-1 ) analogue, were presented at the American Diabetes Association ( ADA ) 76th Scientific S ...


Recent guidelines governing anti-diabetic medications increasingly advocate Metformin as first-line therapy in all patients with type 2 diabetes. However, Metformin could be associated with increased ...


New analyses have shown risk reductions were consistent across age groups for cardiovascular outcomes, including cardiovascular death, with Empagliflozin ( Jardiance ) compared with placebo when added ...


New data showed Empagliflozin ( Jardiance ) reduces the risk for new-onset or worsening kidney disease by 39% versus placebo when added to standard of care in people with type 2 diabetes with establis ...


The FDA ( Food and Drug Administration ) has required labeling changes regarding the recommendations for Metformin-containing medicines for diabetes to expand Metformin’s use in certain patients with ...


The FDA ( Food and Drug Administration ) has found that type 2 diabetes medicines containing Saxagliptin and Alogliptin may increase the risk of heart failure, particularly in patients who already hav ...


New data from a clinical trial led by cardiologists at Brigham and Women's Hospital ( BWH ) and the Duke Clinical Research Institute indicates that the non-statin, cholesterol-lowering drug Ezetimibe ...